Skip to main content

Table 3 Relative risk estimates for REN and AGT interactions:

From: Maternal angiotensinogen (AGT) haplotypes, fetal renin (REN) haplotypes and risk of preeclampsia; estimation of gene-gene interaction from family-triad data

A: Relative risk estimates (95% CI; p-value) for fetal RENhaplotypes when mothers carry the protective AGThaplotype C-T-A (n = 57 family-triads)
RENhaplotype Frequency (%) Single dose Double dose
A-G-C 61.3 0.62 (0.22-1.71); 0.36 0.33 (0.09-1.19); 0.09
A-t-C 29.4 1.03 (0.38-2.82); 0.96 0.62 (0.14-2.79); 0.54
c-G-t 8.9 1.29 (0.50-3.25); 0.59 Not estimable
B: Relative risk estimates (95% CI; p-value) for fetal REN haplotypes when mothers do not carry the protective AGT haplotype C-T-A (n = 27 family-triads)
REN haplotype Frequency (%) Single dose Double dose
A-G-C 55.2 1.53 (0.16-14.90); 0.71 1.0 (0.08-12.4); 0.99
A-t-C 38.0 2.40 (0.24-24.10); 0.46 0.89 (0.06-15.20); 0.93
c-G-t 5.8 0.60 (0.09-4.14); 0.60 Not estimable
  1. SNP order for REN: rs5705 (A/c), rs1464816 (G/t) and rs3795575 (C/t)